Mining and Biosynthesis of Bioactive Lanthipeptides From Microorganisms

Area of Science:

• Microbiology
• Biochemistry
• Drug Discovery

Background:

• Antimicrobial resistance (AMR) is a critical global health challenge, with a declining pipeline of new antimicrobial drugs.
• The rise of multidrug-resistant (MDR) pathogens necessitates novel strategies for discovering effective treatments.
• Natural products (NPs), particularly lanthipeptides, offer a diverse chemical scaffold for developing new antimicrobial agents.

Purpose of the Study:

• To review recent advancements in the discovery and development of microbial-derived lanthipeptides.
• To emphasize the potential of lanthipeptides as a source of novel drug candidates against MDR pathogens.
• To highlight the role of modern technologies in lanthipeptide research.

Main Methods:

• Genome mining for identifying novel lanthipeptide biosynthetic gene clusters.
• Biosynthetic engineering approaches to produce and characterize lanthipeptides.
• Literature review of recent studies on microbial lanthipeptide discovery and development.

Main Results:

• Lanthipeptides, a class of ribosomally synthesized and post-translationally modified peptides (RiPPs), exhibit significant structural diversity and varied mechanisms of action.
• Genome mining and biosynthetic engineering have successfully identified and characterized numerous new lanthipeptides.
• These findings underscore the value of lanthipeptides as a promising resource for combating antimicrobial resistance.

Conclusions:

• Microbial-derived lanthipeptides represent a valuable and largely untapped resource for addressing the urgent need for new antimicrobial drugs.
• Continued exploration through advanced technologies like genome mining and biosynthetic engineering is crucial for unlocking the therapeutic potential of these compounds.
• Lanthipeptides hold significant promise for the development of next-generation treatments against multidrug-resistant pathogens.